Additional Listing

18 Apr 2007 12:20

VASTox plc18 April 2007 VASTox plc ("VASTox" or "the Company") Additional Listing of Shares Oxford, UK, 18 April 2007 -Application has today been made for 505,430 ordinaryshares of 10p each in the Company ("Ordinary Shares") to be admitted to tradingon the London Stock Exchange's AIM market for listed securities ("Admission"). The new Ordinary Shares are being issued pursuant to the exercise of options byformer employees of DanioLabs Limited. Admission is expected to become effectiveon 24 April 2007. Following the admission of these shares the total number of Ordinary Shares inissue will be 49,625,941 Ordinary Shares. - ends - For more information, please contact: VASToxSteven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443951Darren Millington, Chief Financial Officer Citigate Dewe RogersonMark Swallow / David Dible / Valerie Auffray Tel: +44 (0)207 638 9571 About VASTox plc VASTox is a leading UK biotechnology company that discovers and developsproprietary new drugs. The Company's internal drug development programmes areunderpinned by its advanced chemistry and drug screening (chemical genomics)technology platforms, which it also provides on a collaborative orfee-for-service basis to the pharmaceutical industry. VASTox has a broad range of drug discovery programmes in the clinical,pre-clinical and discovery stages of development, which target serious diseaseswith a high unmet medical need. These therapeutic areas include neuro-disorders(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,oncology and regenerative medicines. VASTox's in-house drug development capabilities combine world-class expertise inboth medicinal and carbohydrate chemistry with high-volume, high-contentscreening using its proprietary zebrafish and fruitfly technologies (chemicalgenomics). These whole organism screens have the potential to dramaticallydecrease the time and cost of drug discovery and development by delivering datathat are highly predictive of the efficacy and toxicity of potential drugcompounds in humans. The company listed on the AIM market of the London Stock Exchange in October2004 - symbol: VOX Further information about the company is available at www.vastox.com This information is provided by RNS The company news service from the London Stock Exchange